NCT02294539 is a Phase 4 clinical trial of Losartan 50mg/amlodipine 5mg in Hypertension, sponsored by Chong-Jin Kim.

Who is sponsoring NCT02294539?

NCT02294539 is sponsored by Chong-Jin Kim.

What drugs are being tested in NCT02294539?

Interventions in NCT02294539: Losartan 50mg/amlodipine 5mg, Losartan 100mg/amlodipine 5mg, Losartan 50mg/Hydrochlorothiazide 12.5mg, Losartan 100mg/Hydrochlorothiazide 25mg.

What condition does NCT02294539 study?

NCT02294539 studies Hypertension.

Is NCT02294539 still recruiting?

NCT02294539 is currently completed. Last updated 14 March 2017.

Last reviewed 2017-03-14 · How we verify

NCT02294539

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controlled, Phase 4 Randomized Trial

Completed Phase 4 Last updated 14 March 2017

What this trial tests

Phase 4 trial testing Losartan 50mg/amlodipine 5mg in Hypertension in 231 participants. Completed in 18 May 2016.

Timeline

1 August 2014

Primary endpoint
18 May 2016

18 May 2016

Quick facts

Lead sponsor	Chong-Jin Kim
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	231
Start date	1 August 2014
Primary completion	18 May 2016
Estimated completion	18 May 2016
Sites	1 location across South Korea

Drugs / interventions tested

Losartan 50mg/amlodipine 5mg — full drug profile →
Losartan 100mg/amlodipine 5mg — full drug profile →
Losartan 50mg/Hydrochlorothiazide 12.5mg — full drug profile →
Losartan 100mg/Hydrochlorothiazide 25mg — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Chong-Jin Kim — full company profile →

Who can join

Adults 19 to 80, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

change from baseline in msSBP
Time frame: 4 weeks

Sponsor's own description

The purpose of this study is to investigate which combination therapy is more effective for improving the blood pressure (BP) and AM central SBP in hypertensive patients:Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) or ARB plus diuretics

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study.
Cho EJ, Lee HY, Sung KC, Park S, et al · · 2019 · cited 5× · PMID 31099387 · DOI 10.1093/ajh/hpz050
Comparison of effects between calcium channel blocker and diuretics in combination with angiotensin II receptor blocker on 24-h central blood pressure and vascular hemodynamic parameters in hypertensive patients: study design for a multicenter, double-blinded, active-controlled,
Oh GC, Lee HY, Chung WJ, Youn HJ, et al · · 2017 · cited 5× · PMID 28879040 · DOI 10.1186/s40885-017-0074-0

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02294539 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chong-Jin Kim
Last refreshed: 14 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02294539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing